Preventing stroke in patients with atrial fibrillation

JAMA

Volumn 281, Issue 19, 1999, Pages 1830-1835

  Ezekowitz, Michael D ^a,b,c   Levine, Jody A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale Clinical Trials Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; WARFARIN;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; STROKE;

EID: 0033583748     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.19.1830     Document Type: Article

References (45)

1. Silverman ME. From rebellious palpitations to the discovery of auricular fibrillation: contributions of Meccans, Lewis and Einthoven. Am J Cardiol. 1994;73: 384-389.
2. Einthoven W. Le te'le'cardiogramme. Arch Intern Physiol. 1906;4:132-164.
3. Lewis T. Auricular fibrillation: a common clinical condition. BMJ. 1909;2:1528.
4. Lewis T. Auricular fibrillation and its relationship to clinical irregularity of the heart. Heart. 1909;1:306-372.
5. Rothberger C, Winterberg H. Ueber den Pulsus irregularis perpetuus. Wien Klin Wochenschr. 1909; 22:1792-1795.
6. Rothberger C, Winterberg H. Vorhofflimmem and Arrhythmia perpetua. Wien Klin Wochenschr. 1909; 22:839-844.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
8. Kannel WB, Abbott RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J. 1983;106:389-396.
9. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-1022.
10. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc. 1990;65:344-359.
11. Langenberg M, Hellemons BS, van Ree JW, et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ. 1996;313:1534.
12. Kopecky SL, Gersh BJ, McGown MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987; 317:669-674.
13. Brugada R, Tapscott T, Czernuszewicz G, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med. 1997;336:905-911.
14. Kopecky SL. Management decisions in lone atrial fibrillation. Hosp Pract. 1992;27:135-150.
15. Gajewski J, Singer RB. Mortality in an insured population with atrial fibrillation. JAMA. 1981;245: 1540-1544.
16. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
17. Stroke Prevention in Atrial Fibrillation Investigators. Design of a multlcenter randomized trial for the Stroke Prevention in Atrial Fibrillation study. Stroke. 1990;21:538-545.
18. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
19. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349-355.
20. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation: the Veterans Affairs Cooperative Study. N Engl J Med. 1992;327:1406-1412.
21. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
22. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: SPAF II study. Lancet. 1994;343:687-691.
23. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low intensity, fixed dose, warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trials. Lancet. 1996;348: 633-638.
24. Pengo V, Zasso A, Barbero F, et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1988;82:433-437.
25. Gullov AL, Koefoel BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-1521.
26. Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. JAMA. 1998;279:1273-1277.
27. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. Arch Intern Med. 1998;158:1316-1320.
28. Fatkin D, Feneley M. Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: the relative note of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. Prog Cardiovasc Dis. 1996;39:57-68.
29. Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 1993;328:750-755.
30. Klein AL, Grimm RA, Black IW, et al. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study: a randomized, controlled trial. Ann Intern Med. 1997;126:200-209.
31. Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J. 1995;129:1204-1215.
32. Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessi MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation. 1997; 96:3710-3720.
33. Ezekowitz MD, James KE, Nazarian SM, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation. 1995;92:2178-2182.
34. Ott A, Breteler M, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study: The Rotterdam Study. Stroke. 1997;28:316-321.
35. Yamanouchi H, Nagura H, Mizutani T, et al. Embolic brain infarction in nonrheumatic atrial fibrillation in a clinicopathologic study in the elderly. Neurology. 1997;48:1593-1597.
36. Zito M, Muscari A, Marini E, et al. Silent lacunar infarcts in elderly patients with chronic nonvalvular atrial fibrillation. Aging. 1996;8:341-346.
37. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotlc therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154: 1449-1457.
38. Larrue V, vonKummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:957-960.
39. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Incressing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J. 1997;134:69-72.
40. Hyleck EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest dose of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
41. Coumadin Aspirin Reinfarctton Study (CARS) Investigators. Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet. 1997;350:389-396.
42. Ezekowitz MD, James K, Radford M, Rickles F, Redmond N. Initiating and maintaining patients on warfarin anticoagulation: the importance of monitoring. J Cardiovasc Pharm Ther. 1999;43-8.
43. Kaatz SS, White RH, Hill J, Mascha E, Humphries JE, Becker DM. Accuracy of laboratory and portable monitor international normalized ratio determinations: comparison with a criterion standard. Arch Intern Med. 1995;155:1861-1867.
44. Massicotte P, Marzinotto V, Vegh P, Adams M, Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr. 1995;127:389-394.
45. Sawicki PT, for the Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA. 1999;281: 145-150.